Adagio Medical Holdings, Inc. (ADGM) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Adagio Medical reported revenue of $21.2M, up 3422.6% from $602,000 the year before. Net income was -$25.1M (a -118.3% net margin), or -$1.51 per diluted share. Gross margin was -3.2% and operating margin was -103.2%. Operating activities generated -$19.0M of cash, leaving -$19.4M of free cash flow. At fiscal year end, Adagio Medical held $43.3M in total assets against $30.9M in total liabilities, including $17.1M of cash and equivalents.
Open the full interactive Adagio Medical financials → Quarterly statements, key ratios, valuation history and price charts.
Adagio Medical Key Stats
| Share Price | $0.12 |
|---|---|
| Market Cap | $2.8M |
| 52-Week Range | $0.12 – $1.91 |
| Shares Outstanding | 22.2 million (basic, 2026 Q2) |
Adagio Medical Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $602,000 | $21.2M |
| Cost of Goods Sold | $84.8M | $21.9M |
| Gross Profit | -$2.7M | -$684,000 |
| Operating Income | -$84.2M | -$21.9M |
| Pre-Tax Income | -$98.2M | -$25.3M |
| Income Tax | -$1.9M | $0 |
| Net Income | -$75.0M | -$25.1M |
| Diluted EPS | — | -$1.51 |
Adagio Medical Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $5.7M | $4.0M | $0 | $0 |
| Net Income | -$10.1M | -$3.3M | -$7.0M | -$6.7M |
| Diluted EPS | -$0.66 | -$0.20 | -$0.31 | -$0.30 |
Adagio Medical Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $20.6M | $17.1M |
| Current Assets | $25.3M | $20.1M |
| Total Assets | $48.4M | $43.3M |
| Current Liabilities | $7.8M | $8.2M |
| Total Long-Term Debt | $16.1M | $21.0M |
| Total Liabilities | $28.5M | $30.9M |
| Shareholders' Equity | $19.9M | $12.4M |
Adagio Medical Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$29.5M | -$19.0M |
| Cash From Investing | -$1.6M | -$374,000 |
| Cash From Financing | $15.6M | $16.1M |
| Free Cash Flow | -$31.1M | -$19.4M |
Figures from Adagio Medical's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Adagio Medical financials page for every line item.
Adagio Medical Company Profile
| Ticker | ADGM |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Laguna Hills, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002006986 |
Frequently Asked Questions
What was Adagio Medical's revenue in fiscal 2025?
Adagio Medical (ADGM) reported revenue of $21.2M for fiscal 2025.
What was Adagio Medical's net income in fiscal 2025?
Adagio Medical reported net income of -$25.1M for fiscal 2025.
What was Adagio Medical's earnings per share (EPS) in fiscal 2025?
Adagio Medical's diluted EPS was -$1.51 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Adagio Medical generate in fiscal 2025?
Adagio Medical generated -$19.4M of free cash flow in fiscal 2025.
What was Adagio Medical's revenue last quarter?
In its most recent reported quarter (2026 Q2), Adagio Medical reported revenue of $0.
How much debt does Adagio Medical have?
Adagio Medical reported $21.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Adagio Medical are outstanding?
Adagio Medical reported a weighted average of 22.2 million basic shares outstanding in 2026 Q2.
What is Adagio Medical's market cap?
Based on its latest closing price, Adagio Medical (ADGM) has a market capitalization of about $2.8M.
When does Adagio Medical's fiscal year end?
Adagio Medical's fiscal year end, as registered with the SEC, is December 31.
Where is Adagio Medical headquartered?
Adagio Medical lists its business address in Laguna Hills, California in its SEC filings.
Adagio Medical Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →